GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapies. It utilizes proprietary platforms to create novel drugs targeting a range of cancers, including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors. The company is particularly noted for its TriKE (Tri-specific Killer Engager) platform, which represents a significant advancement in immuno-oncology treatments. By specializing in these therapeutic areas, GT Biopharma, Inc. plays a critical role in the healthcare sector, particularly within the biotechnology industry. Its products aim to improve treatment outcomes for patients with cancer, contributing to medical advancements and shaping the future of cancer therapy.